vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes
Portfolio Pulse from
vTv Therapeutics announced that the FDA has lifted the clinical hold on its cadisegliatin program, allowing the CATT1 Phase 3 trial for type 1 diabetes to resume. The trial duration will be shortened from 12 to 6 months.
March 17, 2025 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The FDA has lifted the clinical hold on vTv Therapeutics' cadisegliatin program, allowing the CATT1 Phase 3 trial for type 1 diabetes to resume with a shortened duration.
The lifting of the FDA clinical hold is a positive regulatory development for vTv Therapeutics, allowing them to proceed with their Phase 3 trial. This could lead to potential advancements in their product pipeline, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100